SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guerin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)

被引：4
|
作者：
Necchi, A. [1 ]
Catto, J. W. F. [2 ]
Powles, T. B. [3 ]
Guerrero-Ramos, F. [4 ]
Simone, G. [5 ]
Shore, N. D. [6 ]
Salinas, J. [7 ]
Merseburger, A. S. [8 ]
Roumiguie, M. [9 ]
Kitamura, H. [10 ]
Morris, D. [11 ]
Wei, Q. [12 ]
Korkes, F. [13 ]
Hasan, M. [14 ]
Jin, S. [15 ]
Maffeo, J. [15 ]
Hammond, C. [14 ]
Sweiti, H. [14 ]
Somer, R. [14 ]
Chang, S. S. [16 ]
机构：
[1] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp & Sci Inst, Dept Med Oncol, Milan, Italy
[2] Univ Sheffield, Sch Med, Urol Dept, Sheffield, S Yorkshire, England
[3] Queen Mary Univ London, Dept Med Oncol, Barts Canc Ctr, London, England
[4] 12 Octubre Univ Hosp, Dept Urol, Madrid, Spain
[5] IRCCS, Regina Elena Natl Canc Inst, Dept Oncol, Rome, Italy
[6] Carolina Urol Res Ctr, Surg & Oncol Dept, Myrtle Beach, SC USA
[7] CEMAIC Private Med Ctr, Dept Oncol, Cordoba, Argentina
[8] Univ Hosp Schleswig Holstein, Dept Urol, Campus Lubeck, Lubeck, Germany
[9] Inst Univ Canc Toulouse Oncopole CHU, Dept Oncol, Toulouse, France
[10] Toyama Univ, Grad Sch Med & Pharmaceut Sci Res, Dept Urol, Toyama, Japan
[11] Urol Associates PC, Dept Urol, Nashville, TN USA
[12] Sichuan Univ, West China Hosp, Dept Oncol, Chengdu, Peoples R China
[13] Hosp Albert Einstein, Fac Med ABC, Dept Urol, Santo Andre, SP, Brazil
[14] Janssen Res & Dev, Res & Dev, Spring House, PA USA
[15] Janssen Res & Dev, Res & Dev, Lexington, MA USA
[16] Vanderbilt Univ, Med Ctr, Dept Urol, Nashville, TN USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2825
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2407TiP
引用
收藏
页码：S1224 / S1224
页数：1
相关论文
共 50 条
  • [21] SINGLE INSTILLATION OF MITOMYCIN C (MMC) PLUS BACILLUS CALMETTE-GUERIN (BCG) VERSUS BCG ALONE IN HIGH GRADE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
    Weiss, Brian
    Wein, Alan
    Malkowicz, S. Bruce
    Guzzo, Thomas
    JOURNAL OF UROLOGY, 2015, 193 (04): : E294 - E294
  • [22] Safety, tolerability, and preliminary efficacy of TAR-200 in patients with intermediate risk non-muscle-invasive bladder cancer: A phase 1 study.
    van Valenberg, F. Johannes P.
    van der Heijden, Toine
    Cutie, Christopher
    Bhanvadia, Sumeet Kaur
    Keegan, Kirk A.
    Hampras, Shalaka
    Sweiti, Hussein
    Maffeo, John
    Jin, Shu
    Chau, Albert
    Reynolds, Don
    Iarossi, Crysti
    Kelley, April
    Li, Xiang
    Stromberg, Katherine
    Sedelaar, Michiel
    Steenbruggen, Jessica
    Somford, Diederik Meindert
    Witjes, Alfred Alfred
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [23] Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guerin (BCG)-unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C
    Necchi, A.
    Shore, N. D.
    Gupta, S.
    Kulkarni, G.
    Dave, H.
    Kapadia, E.
    Zhao, Q.
    Kamat, A.
    EUROPEAN UROLOGY, 2023, 83 : S748 - S748
  • [24] Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG).
    Balar, Arjun Vasant
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost
    Mourey, Loic
    Krieger, Laurence Eliot Miles
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    De Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [25] First results of the phase Ib-II BladderGATE clinical trial: intravenous atezolizumab plus intravesical bacillus Calmette-Guerin (BCG) upfront combination in BCG-naive high risk non-muscle invasive bladder cancer patients
    Guerrero-Ramos, F.
    De Velasco, G.
    Duenas, M.
    Paramio, J.
    Garcia, V. M.
    Gomez-Canizo, C.
    Rodriguez-Izquierdo, M.
    Hernandez-Arroyo, M.
    Martin-Torres, M. P.
    Alvarez-Rodriguez, P.
    Suarez, C.
    Morales, L.
    Ponce, S.
    Rodriguez-Antolin, A.
    Castellano, D.
    EUROPEAN UROLOGY, 2024, 85 : S1701 - S1701
  • [26] Bacillus Calmette-Guerin (BCG) and alternatives Drug treatment of high-risk non-muscle invasive bladder cancer
    Leucht, K.
    Foller, S.
    Grimm, Marc-Oliver
    UROLOGE, 2021, 60 (11): : 1400 - 1408
  • [27] Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guerin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naive High-grade Non-muscle-invasive Bladder Cancer (BRIDGE)
    Kates, Max
    Chu, Xiangying
    Hahn, Noah
    Pietzak, Eugene
    Smith, Angela
    Shevrin, Daniel H.
    Crispen, Paul
    Williams, Stephen B.
    Daneshmand, Siamak
    Packiam, Vignesh T.
    Porten, Sima
    Westerman, Mary E.
    Wagner, Lynne I.
    Carducci, Michael
    EUROPEAN UROLOGY FOCUS, 2023, 9 (04): : 561 - 563
  • [28] Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG): Updated follow-up from KEYNOTE-057.
    De Wit, Ronald
    Kulkarni, Girish S.
    Uchio, Edward M.
    Krieger, Laurence Eliot Miles
    Boormans, Joost L.
    Roumiguie, Mathieu
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Balar, Arjun Vasant
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Updated Interim Analysis from Keynote-057: Pembrolizumab Monotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
    Krieger, Laurence
    de Wit, Ronald
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Balar, Arjun Vasant
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 52 - 53
  • [30] Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Phase II KEYNOTE-057 trial
    de Wit, R.
    Kulkarni, G. S.
    Uchio, E.
    Singer, E. A.
    Krieger, L.
    Grivas, P.
    Bajorin, D.
    Seo, H. K.
    Mourey, L.
    Kamat, A.
    Nishiyama, H.
    Kapadia, E.
    Nam, K.
    Frenkl, T.
    Balar, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 304 - 304
12345